Ojemda (tovorafenib tablets and oral suspension – Day One Biopharmaceuticals) — Cigna

Initial criteria

• Patient age ≥ 6 months
• Patient has relapsed or refractory disease
• Tumor is positive for ONE of the following: BRAF fusion OR BRAF rearrangement OR BRAF V600 mutation

Approval duration

1 year